

# Naoki Matsumaru

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3660103/publications.pdf>

Version: 2024-02-01

9

papers

46

citations

1937457

4

h-index

1719901

7

g-index

9

all docs

9

docs citations

9

times ranked

37

citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of expedited programs in the United States, as foreign regulatory factors, on clinical development time in Japan. Journal of Clinical Pharmacy and Therapeutics, 2022, , .	0.7	0
2	Clinical development of anticancer drugs can be enhanced using efficacy data of small population clinical trials. Journal of Clinical Pharmacy and Therapeutics, 2022, , .	0.7	0
3	Burden of caring for Alzheimer's disease or dementia patients in Japan, the US, and EU: results from the National Health and Wellness Survey: a cross-sectional survey. Journal of Medical Economics, 2021, 24, 266-278.	1.0	10
4	Humanistic burden among caregivers of patients with Alzheimer's disease or dementia in Japan: a large-scale cross-sectional survey. Journal of Medical Economics, 2021, 24, 181-192.	1.0	12
5	Humanistic and economic burden among caregivers of patients with cancer in Japan. Journal of Medical Economics, 2020, 23, 17-27.	1.0	11
6	Factors associated with humanistic burden and indirect cost among patients with cancer in Japan. Journal of Medical Economics, 2020, 23, 1570-1578.	1.0	2
7	A population-based study of the humanistic burden among cancer patients in Japan. Journal of Medical Economics, 2020, 23, 429-441.	1.0	2
8	Influence of Expedited Programs in the United States on Oncology Drug Development in Japan. Therapeutic Innovation and Regulatory Science, 2019, 53, 199-206.	0.8	6
9	Influence of Breakthrough Therapy Designation in the United States on Oncology Drug Development Timelines in Japan. Pharmaceutical Medicine, 2018, 32, 201-207.	1.0	3